MicroRNAs are biomarkers and potential therapeutic targets for breast cancer. Anacardic acid (AnAc) is a dietary phenolic lipid that inhibits both MCF-7 estrogen receptor α (ERα) positive and MDA-MB-231 triple negative breast cancer (TNBC) cell proliferation with IC 50 s of 13.5 and 35 μM, respectively. To identify potential mediators of AnAc action in breast cancer, we profiled the genome-wide microRNA transcriptome (microRNAome) in these two cell lines altered by the AnAc 24:1n5 congener. Whole genome expression profiling (RNAseq) and subsequent network analysis in MetaCore Gene Ontology (GO) algorithm was used to characterize the biological pathways altered by AnAc. In MCF-7 cells, 69 AnAcresponsive miRNAs were identified, e.g., increased let-7a and reduced miR-584. Fewer, i. e., 37 AnAc-responsive miRNAs were identified in MDA-MB-231 cells, e.g., decreased miR23b and increased miR-1257. Only two miRNAs were increased by AnAc in both cell lines: miR-612 and miR-20b; however, opposite miRNA arm preference was noted: miR-20b-3p and miR-20b-5p were upregulated in MCF-7 and MDA-MB-231, respectively. miR-20b-5p target EFNB2 transcript levels were reduced by AnAc in MDA-MB-231 cells. AnAc reduced miR-378g that targets VIM (vimentin) and VIM mRNA transcript expression was increased in AnAc-treated MCF-7 cells, suggesting a reciprocal relationship. The top three enriched GO terms for AnAc-treated MCF-7 cells were B cell receptor signaling pathway and ribosomal large subunit biogenesis and S-adenosylmethionine metabolic process for AnActreated MDA-MB-231 cells. The pathways modulated by these AnAc-regulated miRNAs suggest that key nodal molecules, e.g., Cyclin D1, MYC, c-FOS, PPARγ, and SIN3, are targets of AnAc activity.
For miRNA RNA-seq
The Truseq Small RNA kit (Illumina) was used to prepare miRNA libraries from 1 μg total RNA. Each Library was individually gel purified on a Novex TBE 6% gel and resuspended in 10uL 10mM Tris-Cl, pH 8.5. Libraries were validated and quantitated by running 1μL on the Agilent Technologies 2100 Bioanalyzer DNA High Sensitivity Chip. 36-cycle single sequencing reads were generated on the Illumina NextSeq500 instrument utilizing the 500 Mid-output v2 (75 cycle) sequencing kit. The resulting samples were divided into 48 FASTQ [15] single-end raw sequencing files representing four conditions: MCF-7 control, MCF-7 treated with AnAc 24:1n5 (MCF-7 AnAc), MDA-MB-231 control, and MDA-MB-231 treated with AnAc 24:1n5 (MDA MB-231 AnAc). These raw data of our RNA-seq are available at Gene Expression Omnibus (GEO) database: accession number GSE78011.
Differential miRNA expression analysis
A total of three biological replicates for each treatment were analyzed, with four flow cell lanes per replicate. Raw sequence data files were downloaded from Illumina's BaseSpace (https:// basespace.illumina.com/) onto the KBRIN server for analysis the miRDeep2 [16] and edgeR [17] . Each of the four single-end raw. FASTQ files for each replicate (representing the four flow cells) was concatenated into one single-end. FASTQ file using the unix cat command. Quality control (QC) of the raw sequence data was performed using FastQC (version 0.10.1) [18] . The FastQC results indicated sequence trimming was not necessary since the minimum quality value for all samples was well above Q30 (1 in 1000 error rate) (data not shown).
Given that this is a miR sequencing project, preliminary adapter trimming was performed on each of the samples using a custom file adaptersToTrim.fa which contains a subset of the Illumina TruSeq Small RNA adapter and primer sequences taken from https://support. illumina.com/content/dam/illumina-support/documents/documentation/chemistry_ documentation/experiment-design/illumina-adapter-sequences_1000000002694-00.pdf Sequences were trimmed of the adapters with Trimmomatric v0.33 [19] . The trimmed sequences were directly aligned to the human hg19 reference genome assembly using the mapper.pl wrapper of the miRDeep2 package (v 0.0.7) [16] . This script used bowtie (version 1.1.1) [20] , generating alignment files in arf format. The aligned sequences were then used as inputs into the miRDeep2 package and the script quantifier.pl. In addition, this script used the mirBase release 21 [21] mature miRNA and miRNA hairpin sequences downloaded from ftp://mirbase.org/pub/mirbase/CURRENT/. The result was a file containing the number of reads mapping to each of the 2,822 human (hsa) miRs for the specific sample. After quantification, the resulting counts for each miR in each sample were combined into a reads matrix. This was accomplished using a custom perl script, createReadMatrix.pl. Differentially expressed miRs were determined using edgeR [17] and a customized R script, Schultz-Klinge. miRNA.R. Using a p-value cutoff of 0.05, the number of differentially expressed miRs in each comparison is shown in Table 1 .
In silico network analysis
We performed pathway and network analysis of differentially expressed genes in MetaCore™ version 6.27 (GeneGO, Thomson Reuters, New York, N.Y.). MetaCore™ is a web-based software suite for multiple applications in systems biology including RNA-seq analysis as used here. MetaCore™ analyses are based on MetaBase (http://metadatabase.org/), a 100% manually-curated integrated database of mammalian biology that contains over 6 million experimental findings on protein-protein, protein-DNA, protein-RNA, and protein-compound interactions; metabolic and signaling pathways; and other information [22] .
Generation of heatmaps: Files of miRNAs significantly altered by AnAc treatment in each cell line were imported into Partek software Version 6.6 (Partek Inc., St Louis, MO.) and Partek Genomic Suite™ was used to generate heatmaps (Fig 1, S1 and S2 Figs). Each hierarchical clustering was created using Euclidean distance as similarity measure for genes and samples. We noted that one of the three MCF-7 AnAc samples appeared to behave as a hybrid between the other two AnAc treated and three control (EtOH)-treated samples (S2 Fig). 
RNA isolation, RT-PCR and quantitative real-time PCR (qPCR) of miRNAs and mRNAs
Cell growth, treatment and RNA isolation and quantification/quality assessment were performed as described above. For miRNA, RNA was converted to cDNA using the Taqman 1 miRNA Reverse Transcription kit (PE Applied Biosystems). For mRNA, RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription kit (PE Applied Biosystems). Primers for hsa-miR-268g, hsa-miR-612, hsa-miR-20b-5p, and hsa-miR-20b-3p were purchased from TaqMan (Advanced miRNA assays) and RNU48 (TaqMan) was used as the reference for normalization [23] . Primers for VIM (Vimentin) 
Transient transfection
MCF-7 and MDA-MB-231 cells were transiently transfected for 24 h with miR-612 mimic, miR-612 inhibitor, Anti-miR ™ negative control #1, or mirVANA™ miRNA mimic negative control #1 (all from Ambion, Life Technologies, Thermo Fisher Scientific, Carlsbad, CA, USA), using Lipofectamine RNAiMAX transfection reagent (Invitrogen, Thermo Fisher Scientific) and Opti-MEM 1 Reduced Serum Medium (Invitrogen, Thermo Fisher Scientific). After 24 h of transfection, cells were treated with ethanol (EtOH, vehicle control) or 13.5 or 35 μM AnAc, for MCF-7 and MDA-MB-231 respectively, in phenol red-free IMEM medium containing 5% DCC-stripped FBS for 48 h prior to MTT assay (CellTiter 96, Promega, Madison, WI, USA). Two separate experiments were performed with quadruplicate wells within each experiment. For analysis of miR-612 expression in transfected cells, the medium was changed 24 h Table 1 . Differentially expressed miRNAs (DEmiRs). The log2-fold change with zero value in the control conditions was arbitrarily set to one and the maximum log2-fold change value and those with zero value in the treatment conditions were arbitrarily set to the minimum log2-fold change value of minus one. The number of differentially expressed genes in each comparison is shown and the number of upregulated genes indicated with the upward arrow and downregulated genes indicated by downward arrow.
after transfection as above, without any treatment and RNA was harvested (see above) a total of 72 h post transfection, i.e., at the same time the MTT assay was performed for qPCR of miR-612 using RNU48 as a control (see above).
Results and discussion
RNA-seq analysis of AnAc-regulated miRNAs MCF-7 luminal A (ERα+) and MDA-MB-231 TNBC (triple negative breast cancer) cells were incubated in hormone-depleted medium for 48 h prior to a 6 h treatment with the previously established IC 50 concentrations of AnAc 24:1n5 for MCF-7 (13.5 μM) and MDA-MB-231 (35.0 μM) cells [13] . The 6 h time point was selected based on transcriptome studies in MCF-7 cells to identify primary gene targets [28] and because AnAc 24:1n5 has no overt effect on the viability of either MCF-7 or MDA-MB-231 at that time [13, 29] . The goal was to identify early miRNA changes in response to AnAc 24:1n5 in each cell line. For target analysis, only miRNA transcripts that showed a log2 fold-change greater than 1 (or -1 for repressed miRNAs) were included. Differentially expressed miRNAs (DEmiRs) were identified for four pairwise comparisons (MCF-7 AnAc-treated vs. MCF-7 control; MDA-MB-231 AnAc-treated vs. MDA-MB-231 control; MCF-7 and MDA-MB-231 AnAc treated vs. MCF-7 and MDA-MB-231 control; MDA-MB-231 AnAc treated and control vs. MCF-7 AnAc treated and control) using the tuxedo suite of programs including cufflinks and cuffdiff (version 2.2.1) [30, 31] . Significant DEmiRs with fold-change and p values are listed in S1 and S2 Tables. The number of DEmiRs  in each comparison is shown in Table 1. Tables 2-5 list the AnAc-regulated miRNAs in MCF-7 and MDA-MB-231 cells, their genomic location and host gene (if applicable) (Fig 1) . These data suggest that AnAc selectivity alters miRNA transcript expression in these two cell lines through mostly non-overlapping mechanisms.
As shown in the Venn Diagrams of Fig 2, there were no common downregulated miRNAs in AnAc-treated MCF-7 and MDA-MB-231 cells. Only two miRNA were commonly upregulated by AnAc in both MCF-7 and MDA-MB-231 cells: miR-20b and miR-612 (Fig 2, Table 2 ). The common GO Processes for upregulated miR-20b and miR-612 were identified by MetaCore™ analysis and listed in Fig 2; however no matches between genes/proteins for miR-20b and miR-612 were identified in Pathway Maps by MetaCore analysis. Interestingly, AnAc increased miR-20-3p in MCF-7 and miR-20-5p in MDA-MB-231 cells. This suggests that distinct miR-20b targets would be expected to be regulated in response to AnAc upregulation of miR-20b-3p versus miR-20-5p in the two cell lines. The selection of which mature miRNA 5p or 3p arm is dominant is determined by thermodynamic and structural properties of the processed pre-miR-duplex AGO protein (reviewed in [32] ). The functional consequences of arm selection are therefore distinct. The exact mechanism of miRNA Induced Silencing Complex (miRISC) assembly remains elusive and includes a human miRNA loading complex containing the ds-pre-miRNA, DICER1, TRBP2 and miRNA-free AGO protein as its components. [33] . Recent studies in Huh7 human hepatoma cells showed that an increase in target genes, i. e., SLC7A1 (CAT-1), increased the processing of pre-miR-122 to miR-122, implying that increases in target mRNA levels can promote miRNA biogenesis [33] . Whether this is true for other cells and miRNAs remains to be examined. The MetaCore network enrichment analysis of the miRNAs upregulated in AnAc-treated MCF-7 vs. MDA-MB-231 cells identified "Cellular response to inorganic substance" as the top GO process (S3A Fig). The network analyses for miR-20b and miR-612 are shown in S3A and S3B Fig. There is only one previous examination of miRNAs, mRNAs, and lncRNAs in MCF-7 and MDA-MB-231 cells, but that study used a microarray expression profiling [167] rather than an unbiased RNA-sequencing approach. None of the AnAc-regulated miRNAs was among the miRNAs more highly expressed in MCF-7 compared with MDA-MB-231 cells [167] . In contrast, miR-4284 was more highly expressed in MDA-MB-231 cells [167] and we observed that AnAc decreased miR-4284 in MDA-MB-231 cells ( Table 5 ). The role of miR-4284 in breast cancer is unknown and there are no validated targets of miR-4284, although microRNA.org lists 7,891 putative targets.
miRNAs downregulated by AnAc in MCF-7 cells
Twenty-one miRNAs were downregulated by AnAc in MCF-7 cells (Table 3) . miRNAs are encoded within a gene (intronic or exonic) or are intergenic (reviewed in [168] ). miRNAs can be regulated independently or are cotranscribed with their host gene (reviewed in [8] ). To examine if the miRNA host gene was downregulated by AnAc in MCF-7 cells we searched None validated for 3p. For 5p: DNMT3a [73] miR-520a-5p
Chr19, intergenic. miR-520a-3p inhibits proliferation by targeting HOXD8 in non-small cell lung cancer None experimentally validated for 5p. For 3p: CCND1 and CD44 [74] miR-520d-5p
Chr19, intergenic. involved in HER2-receptor-related differentiation through undefined mechanisms [75] . Overexpression by lentiviral-miR-520d infection of human HLF and Huh7 hepatoma cells converted the cells to non-tumorigenic and less differentiated normal stem cells, but no miRNA target genes were validated [76] . Acts as a tumor suppressor in colorectal cancer [77] .
For 5p: CTHRC1 [77] miR548ag-1
Chr4, intergenic. no publications in PubMed
Chr3, intergenic. Downregulated by E 2 in MCF-7 cells [57]. Down-regulated in aggressive breast tumors [78] . Upregulated in TAM-resistant MCF-7 cells [79] . Upregulated in serum samples from prostate cancer patients compared with benign prostatic hyperplasia patients [80] . Upregulated in recurrent epithelial ovarian cancer (OVCa) [81] . Upregulated in OVCa stem cells, promotes proliferation, invasion, and chemoresistance [82] .
None experimentally validated for 5p. For 3p: FOXO3 and TRIM31 [82] miR-562 Chr2, host gene DIS3L2. Upregulated in serum samples from prostate cancer patients with disseminated disease compared with benign prostatic hyperplasia patients [80] .
EYA1 [83] ; IL22 [84] miR-663a Chr20, intergenic. Upregulated by E 2 in ECC-1 cells [85] . Transcription increased by ZNF224 [86] . Acts as a tumor suppressor and is downregulated in in gastric [87] , colorectal [88] , prostate [89] , breast [86] , hepatocellular [90] , pancreatic [91] , nonsmall cell lung cancer [92] . Transcription factor Ets-2 binds the miR-663 promoter and stimulates transcription in prostate cancer cells [89] .
TP53 (P53) and CDKN1A (p21) [86] JUND [92] TGFB1 [91] HMGA2 [90] miR-664b-5p
ChrX, host gene DKC1. Acts as a tumor suppressor in osteosarcoma [93] and as an oncomiR-in T-cell acute lymphoblastic leukemia [94] and cervical cancer [95] .
None experimentally validated for 5p. For 3p: FOXO4 [96] ; MAT1A [97] ; PLP2 [98] ; SOX7 [93] miR-921 Chr1, host gene FAM78B. Downregulated in bladder cancer [99] . CBR1 [100] miR-1229-5p
Chr 5, host gene MGAT4B. Upregulated in serum of colorectal cancer patients [101] . Overexpressed in breast cancer and correlated with poor prognosis for patients [102] .
None experimentally validated for 5p. For 3p; GSK3B, APC and ICAT [102] .
miR-1287-3p
Chr10, host gene PYROXD2. Downregulated in MCF-7 cells that are aromatase inhibitor resistant [103] . Hypermethylated in cervical cancer [104] , downregulated in larynx carcinoma [105] , anaplastic astrocytomas and/or glioblastomas [106] .
None experimentally validated for 3p. HOXA2 [110] miR4436b-1-3p
Chr2, host gene MALL. Appears to be a strong pathogenic candidate in Autism Spectrum Disorders (ASDs) [111] .
miR4436b-2-3p
Chr2, intergenic. Appears to be a strong pathogenic candidate in ASDs [111] .
(Continued) Chr11, host gene MTRNR2L8. Is transported into mitochondria and inhibits 16S rRNA processing and mitochondrial protein synthesis [112] . Acts as a tumor suppressor in MCF-7 cells in vitro and in MDA-MB-231 cells in xenograft studies in mice [112] .
miR-4516
Chr16, host gene PKD1. Upregulated by fine particulate matter (PM2.5) treatment of A549 NSCLC cells [113] . High expression was associated with infiltrative growth of follicular variant of papillary thyroid carcinomas [114] .
STAT3 [115] , RPL37 [113] miR-4634 Chr5, intergenic. One of five miRNAs in serum that detects breast cancer [116] miR4659a-3p
Chr8, host gene AGPAT5. no publications in PubMed
Chr8, host gene LRRC69. miR-466l upregulates both mRNA and protein expression of IL-10 in macrophages by binding to the 3'UTR of IL10 and inhibiting RNA binding protein-induced transcript degradation [117] . [120] . Upregulated in intermediate monocytes [121] .
ENG [120] miR-6126 Chr16, host gene NAA60. Exosomal tumor suppressor is downregulated in ovarian cancer tumors and is released from ovarian cancer cells [122] .
ITGB1 [122] Chr9, host gene C9orf3. OncomiR, induced by cMyc [123] . Lower expression in MDA-MB-231 than MCF-7 cells [124] . Stimulated by E 2 in ERβ-transfected MCF-7 cells [125] . Involved in regulation of cytoskeletal remodeling and motility [126, 127] . Primary breast tumor expression of mIR-23b correlates with lung metastasis [128] . Metastatic breast cancer cells in patient bone marrow had increased miR-23b [129] . Increased in MCF-7 cell derived exosomes after docosahexaenoic acid (DHA) treatment [130] . miR-23a is 2.5-fold higher in MDA-MB-231 than MCF-7 cells and downregulates CDH1 resulting in hyperactivation of Wnt/-catenin signaling, EMT, and metastasis [131] .
For 5p: PRODH [132] miR-141-3p
Chr12, intergenic and clustered with miR-200c [133] . Both OncomiR and tumor suppressor miRNA, depending on tissue-type. Expression is repressed by ZEB1 [134] , PELP1 [135] , PLK1, KLF8 [136] , and progesterone [137, 138] and upregulated by p53 [139] . Downregulated in metastatic breast cancer [71] and in basal-like primary tumors [140] . Expression stimulated by treatment of MDA-MB-231 cells with DNA demethylating agent 5-AZA-CdR [141] . Low circulating miR-141 was associated with lower overall survival of breast cancer patients [142, 143] . Overexpression of mIR-141 stimulates brain metastasis in mouse models and high serum miR-141 levels were associated with shorter brain metastasis-free survival in human breast cancer patients [144] . miR-141 expression is higher in docetaxel-resistant breast cancer cell lines [145] .
For 3p: PGR [137] ; CTNNB1 [146] ; EIF4E [145] ; ANP32E [140] miR499a-5p
Chr12, host gene MYH7B. SNP rs3746444 G miR-499A>G was associated with increased breast cancer risk in Chinese population [147] .
For 5p: IFNAR1 [148] miR664b-5p
ChrX, host gene DKC1. No references were found in PubMed.
miR-1247-5p
Chr14, in the DLK1-DIO3 genomic imprinted microRNA cluster [149] . Downregulated in aromatase-resistant MCF-7 breast cancer cells [103] and lung adenocarcinomas [150] . Acts as a tumor suppressor in pancreatic cancer [151] .
Silenced by DNA methylation in lung adenocarcinomas and cell lines and overexpression promotes apoptosis and inhibits cell invasion and migration [152] . Overexpressed in castrationresistant prostate cancer [153] . GSE78011. In AnAc-treated MCF-7 cells, six downregulated host genes for downregulated miRNAs were identified: MiR-548j host gene HMGB1P10; miR-597 host gene TNKS; miR-1915 host gene CASC10; miR-3146 host gene TWISTNB; miR-5187 host gene TOMM40L; and miR-6814 host gene RIPK4. Whether AnAc selectively inhibits the transcription of these genes via its p300/PCAF histone acetyltransferase (HAT) inhibitory function [169] remains to be examined. Inhibition of HAT activity would be expected to increase gene expression. Interestingly, AnAc inhibits p300/PCAF histone acetyltransferase (HAT) activity [169] and thus could coordinately downregulate this set of miRNAs and host genes by promoting a more condensed genomic state, but experimentally examining the veracity of the supposition is outside this current study and remains to be examined fully. MetaCore transcription factor (TF) network analysis identified CREB1, FosB, SOX4, TCF7L2 (TCF4), PRDM14, JunD, GATA-3, FRA-1, cFos, JunB, FOXp3, and YY1 as significantly associated with these genes. The ability of AnAc to inhibit the activity of these TFs will also need to be experimentally verified. A decrease in a miRNA would be expected to result in an increase its target transcript expression. Validated targets of each miRNA were identified in the literature. An important note in searching the literature for miRNA targets is that often, whether the miRNA# is the 3p or 5p arm is not stated. However, if the miRNA sequence is provided in a diagram along with the seed match site in a target mRNA's 3'-UTR, the miRNA sequence can be identified as either 3p or 5p by entering the miRNA sequence in miRBase.org. Clearly, a miRNA-3p and miRNA-5p will have different targets, and thus potentially different cellular effects. When identified in our RNA seq study, the 3p or 5p arm is indicated. AnAc reduced miR-378g that targets VIM (vimentin) [51] and VIM mRNA transcript expression was increased in AnAc-treated MCF-7 cells (GSE78011), suggesting a reciprocal regulation. None of the other validated targets of decreased miRNAs (Table 3) were found among the upregulated mRNA transcripts identified in GSE78011. MetaCore network enrichment analysis did not match any of the downregulated miRNAs and Pathway Maps, GO processes, or Process Networks. Networks identified were 1) miR-509: positive regulation of macromolecule metabolic process; 2) miR-584: regulation of gene expression; 3) miR-509, miR584, MDM2, ERK1/2: positive regulation of gene expression (S4 Fig). Based on their CSC and tumor-promoting activities the AnAc downregulation of miR-378g, miR-548, miR-548j, miR-548l (Table 3) would be expected to contribute to the anti-proliferative activity of AnAc.
miRNAs upregulated by AnAc in MCF-7
AnAc increased the expression of 48 miRNAs in MCF-7 cells (Table 4 ). None of the host genes (Table 3) of intronic miRNAs was upregulated by AnAc treatment of MCF-7 cells. None of the validated targets of upregulated miRNAs in AnAc-treated MCF-7 cells (Table 4) were found among the AnAc-regulated mRNA transcripts identified in RNA seq (GSE78011). Given their roles as 'tumor suppressor' miRNAs in inhibiting breast and other cancer cell proliferation and activities (see Table 4 ), the increases in let-7a-2-3p, miR-520a-5p, miR-520d-5p, miR551b-5p, miR-612, miR-663a, miR-1287-3p, miR-4485-5p, and miR-6126 may play roles in AnAc-mediated inhibition of breast cancer cell proliferation. miR-520a-5p and miR-520d-5p are in a cluster of miR-520 isomers (a-h) on Chr 19 that share the same seed sequence, and thus are predicted to have common targets. miR-520f was recently reported to target ADAM9, thus inhibiting internalization of E-cadherin, and TGFBR2 that inhibits TGFβ signaling-mediated induction of ZEB1/2 and/or SNAI which thus allows CDH1 (E-cadherin) transcription, thus blocking EMT [170] .
MetaCore analysis of these miRNAs identified "embryo implantation, cellular response to amino acid stimulus" as the top GO process ( S5A Fig). Network analysis identified two top networks: 1) mi-1229-3p, miR-520a-5p, miR-612, miR-4516, miR-562: positive regulation of metabolic process (S5B Fig); and 2 ) miR 20b-3p, miR 663a, let-7a-5p, miR-1229 -3p, SMAD3: regulation of cell proliferation ( S5C Fig). Network analysis of TFs associated with the 48 upregulated miRNAs identified c-Myc, N-Myc, EPAs1, E2F1, SOX2, AML1, RUNX10, NANOG, MITF, EGR1, and ZNF224 in the top ten TFs. Whether AnAc may activate these TFs to increase the transcription of the upregulated miRNAs or selectively increase miRNA stability will require further examination.
miRNAs oppositely regulated by AnAc in MCF-7 and MDA-MB-231 cells
In contrast, miR-6873 showed opposite AnAc regulation in the two cell lines: it was downregulated in MCF-7 and upregulated in MDA-MB-231 cells (Tables 2 and 5 ). There are no publications in PubMed on miR-6873 and miR-6873 was not listed in microRNA.org or miRTarBase. Thus, its relevance to AnAc responses in these two cell lines is unknown.
miRNAs downregulated by AnAc in MDA-MB-231 cells
Twenty-two miRNAs were downregulated by AnAc in MDA-MB-231 cells and none of these overlapped with miRNAs downregulated by AnAc in MCF-7 cells (Table 5 ). The chromosome location and host gene, if warranted, of each of the AnAc-downregulated miRNAs are identified in Table 5 . To examine if the miRNA host gene was downregulated by AnAc in MDA-MB-231 cells, we searched GSE78011. miR-1277 host gene WDR44 was downregulated by AnAc in MDA-MB-231 cells. WDR44 encodes a protein that interacts with the small GTPase rab11 and is involved in endosome recycling [171] . There are no validated targets for miR-1277 in miRTarBase.
Downregulation of a miRNA would be expected to increase the expression of its targets; hence, we searched our data of mRNAs upregulated by AnAc in MDA-MB-231 cells (550 genes, GSE78011) for the validated targets in Table 5 , but none were reciprocally upregulated. This may be because the miRNA and mRNA for RNA seq were extracted at the same time, i.e., after 6 h of AnAc treatment, or that these mRNAs are not expressed or targeted in MDA-MB-231 cells. Given their roles as putative oncomiRs the downregulation miR-23b and miR-1247 may play a role in the anti-proliferative activity of AnAc in in MDA-MB-231 cells.
Analysis of the data identified ZFP36L1 as a putative target of miR-3614 in MDA-MB-231 cells. Interestingly, AnAc downregulated miR-3614 and upregulated ZFP36L1 transcript expression in MDA-MB-231 cells, suggesting an inverse correlation. ZFP36L1 has been identified as a cancer gene due to mutations in breast cancer and acts in a recessive manner [172] . ZFP36L1 is a member of the TTP family of tandem zinc finger proteins that bind AU-rich elements (AURE) in the 3 0 -end of target gene transcripts and promote target degradation, e.g. STARD1 [173] , VEGFA [174] , NR4A2 [175] , BCL2 [176] , LDLR [177] , STAT5B [178] , and CDK6 [179] . Of these genes, only VEGFA and LDLR were identified as differentially expressed genes in AnAc-treated cells. LDLR was downregulated whereas VEGFA was upregulated in AnAc-treated MDA-MB-231 cells. Interestingly, medroxyprogesterone acetate (MPA, a synthetic progestin), but not E 2 , upregulates ZFP36L1 transcription in MCF-7 cells [25] . (Table 6) . We have described miR-20b-5p and miR-612 upregulation in the context of similar results in AnAc-treated MCF-7 cells (Table 2, Fig 2, S2 Fig) . The chromosome location and host gene, if warranted, of each of the AnAc-upregulated miRNAs are identified in Table 6 . Interestingly, most of the downregulated miRNAs were intergenic. miR-1298 is in encoded in HTR2C, but HTR2C was not among the AnAc-regulated genes in MDA-MB-231 cells in GSE78011. An increase in a miRNA would be expected to result in a decrease of its target transcript. miR20b-5p target EFNB2 (ephrin B2) expression was downregulated in AnAc-treated MDA-MB-231 cells, but none of the validated targets of the upregulated miRNAs (Table 6) were found among the AnAc-downregulated mRNA transcripts identified in RNA seq (GSE78011). Given their roles as 'tumor suppressor' miRNAs (see Table 6 ), the increases in miR-29b, miR-612, and miR-1298 may contribute to the antiproliferative activity of AnAc in MDA-MB-231 cells.
MetaCore analysis of these upregulated miRNAs identified "cellular response to inorganic substance" as the top GO process (S7A Fig). MetaCore analysis identified two networks: 1) Table 6 . miRNAs upregulated by AnAc in MDA-MB-231 cells. The genomic location of each miRNA was identified in miRAD http://bmi.ana.med.uni-muenchen.de/miriad/ [34]. Verified targets are those experimentally validated targets of the indicated miRNA as demonstrated by 3'-UTR luciferase reporter assay. Since many publications do not include whether the 5p or 3p arm of the miRNA was studied, if the sequence of the miRNA was provided, it was searched in miRBase.org to identify which arm was used in the target gene 3'-UTR luciferase reporter assay.
miRNA
Role in breast or other cancers Verified targets miR-378f Chr1, intergenic. Downregulated by E6/E7 silencing in HeLa cells [161] .
miR-1257 Chr20, intergenic. Downregulated in dedifferentiated liposarcoma [162] .
miR-1298-5p
ChrX, host gene HTR2C clustered with miR-764, miR1912, miR1264, miR-1911, and miR-448. Downregulated in neuroglioma [163] . Identified as an inhibitor the growth of KRASdriven colon cancer cells both in vitro and in vivo [164] .
For 5p: GJA1 [165] , PTK2 and LAMB3 [164] miR-1304-5p
Chr11, intergenic. Downregulated in NSCLC cells [166] . 
qPCR validation of select AnAc-mediated changes in miRNAs
We selected miR-612, increased by AnAc in both MCF-7 and MDA-MB-231 cells (Table 2) ; miR-20b-3p and miR-29-5p, upregulated by AnAc in MCF-7 and MDA-MB-231, respectively (Table 2) , and miR-378g that was downregulated by AnAc in MCF-7 cells for validation. miR378g was selected because miR-378g targets VIM [51] and VIM mRNA transcript expression was increased in AnAc-treated MCF-7 cells (GSE78011), suggesting a reciprocal regulation. Cells were grown in hormone-depleted medium for 48 h prior to 6 h treatment with 13.5 or 35 μM AnAc. As anticipated, AnAc increased miR-612 in both cell lines (Fig 3A) . Also as anticipated, AnAc increased miR-20b-3p in MCF-7 cells. We did not detect the anticipated decrease in miR-378g in AnAc-treated MCF-7 cells; however, AnAc reduced miR-378g in MDA-MB-231 cells. We did not detect miR-20b-5p in MDA-MB-231 cells (CT values were undetermined). CT values show that miR-20b-3p is the dominant arm of miR-20b expressed in both cell lines (Fig 3B) .
Effect of altered miR-612 on cell viability
Since AnAc increased miR-612 in both MCF-7 and MDA-MB-231 cells ( Fig  4A) . As expected, AnAc inhibited cell viability in both cell lines (Fig 4B) . Transfection with miR-612 mimic inhibited cell viability in each cell line with a larger effect in MCF-7 than MDA-MB-231 cells. Transfection with a miR-612 inhibitor had no effect in MCF-7 cells, but inhibited the viability of MDA-MB-231 cells~20%. Notably, the miR-612 inhibitor abrogated the anti-proliferative activity of AnAc in MCF-7 cells and reduced AnAc's anti-proliferative activity in MDA-MB-231 cells. These results are consistent with a model in which the increase in miR-612 in AnAc-treated MCF-7 and MDA-MB-231 cells plays a role in the anti-proliferative activity of AnAc (Fig 4C) . 
qPCR validation of AnAc-mediated changes in mRNAs targeted by miR378g
We selected VIM, a target of miR-378g downregulated by AnAc in MCF-7 cells, and ZFP36L, a target of miR-3614 downregulated by AnAc in MDA-MB-231 cells for validation by qPCR.
As anticipated from the decrease in miR-378g in RNA seq data (Table 3) , we detected a slight increase in VIM transcript expression in MCF-7 as well as an increase in VIM in MDA-MB-231 cells (Fig 5) . However, because qPCR indicated an increase in miR-378g levels in AnActreated MCF-7 cells (Fig 5) , it is possible that VIM is upregulated by AnAc by mechanisms unrelated to miR-378g. In addition, miRNA and mRNA were extracted at the same time, i.e., after 6 h of AnAc treatment, and it may be that changes in VIM mRNA levels require a longer time to be degraded after miR-378g targeting. Transcript levels of ZFP36L were increased in AnAc-treated MDA-MB-231 cells (Fig 5) , corresponding with the observed downregulation of miR-3614 (Table 5 ). These data confirm the reciprocal expression of these mRNA transcripts detected in RNA seq and their target miRNAs in the respective AnAc-treated cell line.
Pathways affected by DEGs and DEmiRs in AnAc-treated MCF-7 cells
MetaCore analysis of DEGs from both mRNA and miRNA data sets of AnAc-treated MCF-7 cells identified NETosis in SLE as the top pathway. The release of neutrophil extracellular traps (NETs) by dying cells (NETosis) was first described as the release of nuclear chromatin, nuclear histones and many granular antimicrobial proteins from neutrophils as one of the first lines of defense against pathogens (reviewed in [180] ). The top GO processes were chromatin silencing, negative regulation of gene expression (epigenetic, nucleosome assembly, chromatin assembly, and nucleosome organization. The three gene networks identified were 1): PDEGF PDE6G, APOBEC3H, GGTF II beta, CDIP, p53; 2) miR-499, BMCC1, Histone H1, miR-20b, miR-23b; 3) UCHL1, Protein C, PDK4, EGR1, miR-1298 5p. Network #2 processes include anoikis, negative regulation of fat cell proliferation, regulation of DNA metabolic processes, which reflect the antiproliferative, pro-apoptotic, and NRAM activity of AnAc detected previously in MCF-7 cells [13] .
Pathways affected by DEGs and DEmiRs in AnAc-treated MDA-MB-231 cells
MetaCore analysis of DEGs from both mRNA and miRNA data sets of AnAc-treated MDA-MB-231 cells identified "Immune response, IL-3 signaling via JAK/STAT, p38, JNK, and NFkB" as the top pathway. The top GO processes were "Positive regulation of biological process; cellular response to oxygen-containing compound, positive regulation of cellular process, response to oxygen-containing compound, regulation of developmental process, and response to lipid". The three gene networks identified were Network #1: Axin, Frizzled, cMyc, WNT, PI3K reg classIA: canonical Wnt signaling pathway, beta-catenin destruction complex disassembly, regulation of cell proliferation, cell surface receptor signaling pathway involved in cell-cell signaling, cell-cell signaling by wnt. Network #2: C/ EBPbeta, SOS, NGFR, H-Ras, NGF: positive regulation of cellular metabolic process, positive regulation of MAPK cascade, positive regulation of metabolic process, positive regulation of macromolecule metabolic process, and positive regulation of intracellular signal transduction. Network #3: GALNT4, Keratin80, BCMP101, HEXIM1, PNRC1: translational elongation, translation, amide biosynthetic process, peptide biosynthetic process, peptide metabolic process. 
Conclusions
In summary, we describe the first comprehensive assessment of miRNA expression in response to anacardic acid in ERα+, luminal A MCF-7 and MDA-MB-231 TNBC breast cancer cells. The pathways modulated by these miRNAs suggest that key nodal molecules, e.g., Cyclin D1, SMAD, SP1, MYC, c-FOS, PPARγ, BCL2, FOXO3A, MDA2, and SIN3, are targets of AnAc activity. In agreement with the pathway analysis, we previously reported that AnAc reduced CCND1 transcript expression in MCF-7 and MDA-MB-231 cells [13] . The roles of the other proteins and pathways in AnAc responses remains to be investigated. 
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